Prostate Adaptive Radiation Therapy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorRoyal North Shore Hospital

About this trial

Prostate ART is a two phase study looking at using adaptive radiotherapy to help reduce toxicity for prostate cancer patients.

Adaptive radiotherapy is a new technology that provides the ability to account for daily changes in anatomy. Adaptive radiotherapy also provides a foundation for which radiotherapy margins might be safely reduced.

Phase 1 of this study is looking to see if a radiation therapist centred adaptive workflow can be implemented. If phase 1 of this study is safe and feasible, the study will proceed to phase 2.

Part 2 of the study looks at using adaptive technology to reduce radiation treatment margins. The primary aim of this study is to see whether margin reduced treatment using adaptive radiotherapy can reduce side effects for prostate cancer patients.

Eligibility criteria

Qualifiers

- Age > 18

Biopsy proven prostate malignancy

Definitive treatment is radiotherapy to the prostate alone

ECOG performance status 0-2

Disqualifiers

Hip prosthesis

Patient separation from prostate centre to skin edge > 24cm, measured on diagnostic scan-

Trial design

Treatments tested in this trial

  • Adaptive radiotherapy +/- Margin Reduction
  • Image guided radiotherapy

Treatment groups

130 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Royal North Shore Hospital

Lead sponsor

Northern Sydney and Central Coast Area Health Service

Collaborator